Literature DB >> 24967152

Diagnostic imaging dilemma of a clival lesion and its clinical management implications.

Sung-Joo Yuh1, John Woulfe2, Martin J Corsten3, Ricardo L Carrau4, Daniel M Prevedello5, Amin B Kassam1.   

Abstract

Background A retroclival lesion can represent a notochordal remnant-derived mass. The differential diagnoses includes benign lesions such as ecchordosis physaliphora (EP) and neuroenteric cyst or malignant ones such as chordomas. In the case of EP and chordoma, although both types arise from remnants of fetal notochord tissues, they represent two separate entities with different radiographic and biologic behaviors. Case Description We present a case of an incidental finding of a retroclival lesion. The magnetic resonance imaging (MRI) characteristics of the lesion match the neuroimaging profile of a benign lesion and are suggestive of an EP. There was no enhancement noted with the addition of gadolinium. Nonetheless, pathology determined the lesion to be a malignant chordoma. Conclusion The differential diagnosis of a retroclival lesion includes benign and malignant notochordal lesions. Here we present a case of a patient with an incidental finding of a retroclival lesion. Radiographic findings were suggestive of a benign lesion, possibly EP, yet the pathology revealed a chordoma. This report suggests that despite benign imaging, chordoma cannot be excluded and the implications for treatment can be significant. It is important to achieve the correct diagnosis because the prognostic and therapeutic implications are different.

Entities:  

Keywords:  benign; chordoma; ecchordosis physaliphora; enhancement; gadolinium; malignant; neuroenteric cyst

Year:  2014        PMID: 24967152      PMCID: PMC4067752          DOI: 10.1055/s-0033-1363171

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  33 in total

1.  Neuroradiologic-pathologic correlation in a neurenteric cyst of the clivus.

Authors:  Vibhu Kapoor; Douglas R Johnson; Melanie B Fukui; William E Rothfus; Hae D Jho
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Intracranial laterally based supratentorial neurenteric cyst.

Authors:  G S Tan; T Hortobágyi; S Al-Sarraj; S E J Connor
Journal:  Br J Radiol       Date:  2004-11       Impact factor: 3.039

Review 3.  [A surgical case of ecchordosis physaliphora].

Authors:  J Akimoto; H Takeda; T Hashimoto; J Haraoka; H Ito
Journal:  No Shinkei Geka       Date:  1996-11

4.  Cervical ecchordosis physaliphora: CT and MR features.

Authors:  S H Ng; S F Ko; Y L Wan; L M Tang; Y S Ho
Journal:  Br J Radiol       Date:  1998-03       Impact factor: 3.039

Review 5.  Neuroradiological characteristics of ecchordosis physaliphora. Case report and review of the literature.

Authors:  H Toda; A Kondo; K Iwasaki
Journal:  J Neurosurg       Date:  1998-11       Impact factor: 5.115

6.  Intradural chordoma without bone involvement: nuclear magnetic resonance (NMR) appearance. Case report.

Authors:  T B Mapstone; B Kaufman; R A Ratcheson
Journal:  J Neurosurg       Date:  1983-09       Impact factor: 5.115

7.  Sudden death due to subarachnoid bleeding from ecchordosis physaliphora.

Authors:  T Fracasso; B Brinkmann; W Paulus
Journal:  Int J Legal Med       Date:  2007-09-05       Impact factor: 2.686

8.  Ecchordosis physaliphora and chordoma: a comparative ultrastructural study.

Authors:  K L Ho
Journal:  Clin Neuropathol       Date:  1985 Mar-Apr       Impact factor: 1.368

9.  Endoscopic endonasal approach for clival chordomas.

Authors:  Martina Stippler; Paul A Gardner; Carl H Snyderman; Ricardo L Carrau; Daniel M Prevedello; Amin B Kassam
Journal:  Neurosurgery       Date:  2009-02       Impact factor: 4.654

10.  Benign notochordal cell tumors: A comparative histological study of benign notochordal cell tumors, classic chordomas, and notochordal vestiges of fetal intervertebral discs.

Authors:  Takehiko Yamaguchi; Seiichiro Suzuki; Hiroaki Ishiiwa; Ken Shimizu; Yoshihiko Ueda
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.